2016-10-18
Keystone Nano said today that its ceramide nanoliposome won orphan drug status for the treatment of liver cancer. The designation provides the company with a window of market exclusivity upon product approval.
The State College, Penn.-based company touted its nanoliposome delivery system as being able to load both water-loving and water-hating compounds and delivery them intracellularly. The carriers range from 60-80 nanometers and are stable in circulating blood.
Get the full story at our sister site, Drug Delivery Business News.
The post Keystone Nano wins orphan designation for ceramide liver cancer treatment appeared first on MassDevice.